General information about company				
Scrip code 532167				
NSE Symbol				
MSEI Symbol				
ISIN*	INE501C01015			
Name of company	OMKAR PHARMACHEM LIMITED			
Type of company				
Class of security	Equity			
Date of start of financial year	01-04-2023			
Date of end of financial year	31-03-2024			
Date of board meeting when results were approved	30-05-2024			
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	22-05-2024			
Description of presentation currency	INR			
Level of rounding used in financial results	Lakhs			
Reporting Quarter	Yearly			
Nature of report standalone or consolidated	Standalone			
Whether results are audited or unaudited	Audited			
Segment Reporting	Single segment			
Description of single segment	Business Support Services			
Start date and time of board meeting	30-05-2024 16:30			
End date and time of board meeting	30-05-2024 17:15			
Whether cash flow statement is applicable on company	Yes			
Type of cash flow statement	Cash Flow Indirect			

Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
---	-----------------------------------

	Financial Results – Ind-AS					
	Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)					
А	Date of start of reporting period	01-01-2024	01-04-2023			
В	Date of end of reporting period	31-03-2024	31-03-2024			
С	Whether results are audited or unaudited	Audited	Audited			
D	Nature of report standalone or consolidated	Standalone	Standalone			
Part I	Blue color marked fields are non-mandatory. For Co months ended, in such case zero shall be inserted in t		any has no figures for 3 months / 6			
1	Income					
	Revenue from operations	13.5	54			
	Other income	0.35	0.35			
	Total income	13.85	54.35			
2	Expenses					
(a)	Cost of materials consumed	0	0			
(b)	Purchases of stock-in-trade	0	0			
(c) Changes in inventories of finished goods, work-in- progress and stock-in-trade 0		0				
(d)	Employee benefit expense	3.63	15.79			
(e)	Finance costs	2.91	2.91			
(f)	Depreciation, depletion and amortisation expense	0.14	0.49			
(f)	Other Expenses					
1	Other Expenses	2.39	9.88			
10						

Total other expenses	2.39	9.88
Total expenses	9.07	29.07

	Financial Results – Ind-AS				
	Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)				
А	Date of start of reporting period	01-01-2024	01-04-2023		
В	Date of end of reporting period	31-03-2024	31-03-2024		
С	Whether results are audited or unaudited	Audited	Audited		
D	Nature of report standalone or consolidated	Standalone	Standalone		
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.				
3	Total profit before exceptional items and tax	4.78	25.28		
4	Exceptional items	0	0		
5	Total profit before tax	4.78	25.28		
7	Tax expense				
8	Current tax	6.37	6.37		
9	Deferred tax	0	0		
10	Total tax expenses	6.37	6.37		
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0		
14	Net Profit Loss for the period from continuing operations	-1.59	18.91		
15	Profit (loss) from discontinued operations before tax	0	0		
16	Tax expense of discontinued operations	0	0		
17	Net profit (loss) from discontinued operation after tax	0	0		
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0		
21	Total profit (loss) for period	-1.59	18.91		

22	Other comprehensive income net of taxes	0	0
----	---	---	---

	Financial Results – Ind-AS					
	Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current perior ended (dd-mm-yyyy)					
А	Date of start of reporting period	01-01-2024	01-04-2023			
В	Date of end of reporting period	31-03-2024	31-03-2024			
С	Whether results are audited or unaudited	Audited	Audited			
D	Nature of report standalone or consolidated	Standalone	Standalone			
Part I	Blue color marked fields are non-mandatory. For Consolida months ended, in such case zero shall be inserted in the said		has no figures for 3 months / 6			
23	Total Comprehensive Income for the period	-1.59	18.91			
24	Total profit or loss, attributable to					
	Profit or loss, attributable to owners of parent					
	Total profit or loss, attributable to non-controlling interests					
25	5 Total Comprehensive income for the period attributable to					
	Comprehensive income for the period attributable to owners of parent	0	0			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0			
26	Details of equity share capital					
	Paid-up equity share capital	1008.37	1008.37			
	Face value of equity share capital	10	10			
27	Details of debt securities					
28	Reserves excluding revaluation reserve		-85.09			
29	Earnings per share					
i	Earnings per equity share for continuing operations					

	Basic earnings (loss) per share from continuing operations	-0.016	0.188
	Diluted earnings (loss) per share from continuing operations	-0.016	0.188
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	-0.016	0.188
	Diluted earnings (loss) per share from continuing and discontinued operations	-0.016	0.188
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	Disclosure of notes on financial results	Textual Information(1)	

Text Block			
	1. The above results have been reviewed by the audit Committee & Approved by the board of Directors at their respective meeting held on 30.05.2024.		
	2. Corresponding previous periods figures are regrouped/rearranged where-ever necessary to make them Comparable.		
Textual Information(1)	3. The Financial Results for the Quarter and year ended on 31.03.2024 has been prepared in accordance with the IND-AS specified under section 133 of the Companies Act and rules made thereunder.		
	4. The IND-AS regarding segment reporting is not applicable to the Company.		
	5. The Figures of the last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year		

	Statement of Asset and Liabilities				
	Particulars Current year ended (dd-mm-yyyy)				
	Date of start of reporting period	01-04-2023			
	Date of end of reporting period	31-03-2024			
	Whether results are audited or unaudited	Audited			
	Nature of report standalone or consolidated	Standalone			
	Assets				
1	Non-current assets				
	Property, plant and equipment	0.81			
	Capital work-in-progress	0			
	Investment property	0			
	Goodwill	0			
	Other intangible assets	0			
	Intangible assets under development	0			
	Biological assets other than bearer plants	0			
	Investments accounted for using equity method	0			
	Non-current financial assets				
	Non-current investments	930			
	Trade receivables, non-current	0			
	Loans, non-current	0			
	Other non-current financial assets	0			
	Total non-current financial assets	930			
	Deferred tax assets (net)	10.02			

	Total current assets	18.41
	Other current assets	6.49
	Current tax assets (net)	0
	Total current financial assets	11.92
	Other current financial assets	0
	Loans, current	0
	Bank balance other than cash and cash equivalents	0
	Cash and cash equivalents	7.16
	Trade receivables, current	4.76
	Current investments	0
	Current financial asset	
	Inventories	0
2	Current assets	
	Total non-current assets	940.83
	Other non-current assets	0

	Statement of Asset and Liabilities	
	Particulars	Current year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2023
	Date of end of reporting period	31-03-2024
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	959.24
	Equity and liabilities	
	Equity	
	Equity attributable to owners of parent	
	Equity share capital	1008.37
	Other equity	-85.09
	Total equity attributable to owners of parent	923.28
	Non controlling interest	
	Total equity	923.28
Liabilities		
Non-current liabilities		
	Non-current financial liabilities	
	Borrowings, non-current	0
	Trade payables, non-current	0
	Other non-current financial liabilities	0
	Total non-current financial liabilities	0

Provisions, non-current	0.43
Deferred tax liabilities (net)	0
Deferred government grants, Non-current	0
Other non-current liabilities	0
Total non-current liabilities	0.43
Current liabilities	
Current financial liabilities	
Borrowings, current	30.31
Trade payables, current	1.77
Other current financial liabilities	0
Total current financial liabilities	32.08
Other current liabilities	3.45
Provisions, current	0
Current tax liabilities (Net)	0
Deferred government grants, Current	0
Total current liabilities	35.53
3 Liabilities directly associated with assets in disposal group classified as held for sale	0
4 Regulatory deferral account credit balances and related deferred tax liability	0
Total liabilities	35.96
Total equity and liabilites	959.24
Disclosure of notes on assets and liabilities	

	Format for Reporting Segmenet wise Reven	ue, Results and Capital Emj	ployed along with the company results
	Particulars	3 months/ 6 month ended (dd- mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-01-2024	01-04-2023
	Date of end of reporting period	31-03-2024	31-03-2024
	Whether accounts are audited or unaudited	Audited	Audited
	Nature of report standalone or consolidated	Standalone	Standalone
1	Segment Revenue (Income)		
	(net sale/income from each segment should be disclosed)		
	Total Segment Revenue		
	Less: Inter segment revenue		
	Revenue from operations		
2	Segment Result		
	Profit (+) / Loss (-) before tax and interest from eac	h segment	
	Total Profit before tax		
	i. Finance cost		
	ii. Other Unallocable Expenditure net off Unallocable income		
	Profit before tax		
3	(Segment Asset - Segment Liabilities)		
	Segment Asset		
	Total Segment Asset		
	Un-allocable Assets		
	Net Segment Asset		
4	Segment Liabilities		

E

Segment Liabilities	
Total Segment Liabilities	
Un-allocable Liabilities	
Net Segment Liabilities	
Disclosure of notes on segments	

Cash flow statement, indirect			
	Particulars		
А	Date of start of reporting period	01-04-2023	
В	Date of end of reporting period	31-03-2024	
С	Whether results are audited or unaudited	Audited	
D	Nature of report standalone or consolidated	Standalone	
Part I	Blue color marked fields are non-mandatory.		
	Statement of cash flows		
	Cash flows from used in operating activities		
	Profit before tax	25.28	
	Adjustments for reconcile profit (loss)		
	Adjustments for finance costs	0	
	Adjustments for decrease (increase) in inventories	0	
	Adjustments for decrease (increase) in trade receivables, current	1.71	
	Adjustments for decrease (increase) in trade receivables, non-current	0	
	Adjustments for decrease (increase) in other current assets	0	
	Adjustments for decrease (increase) in other non-current assets	0	
	Adjustments for other financial assets, non-current	0	
	Adjustments for other financial assets, current	0	
	Adjustments for other bank balances	0	
	Adjustments for increase (decrease) in trade payables, current	-0.83	
	Adjustments for increase (decrease) in trade payables, non-current	0	
	Adjustments for increase (decrease) in other current liabilities	0	

-2.9
-2.9
-2.9
-2.9
26.
1.
0

Cash flows from used in investing activities	
Cash flows from losing control of subsidiaries or other businesses	
Cash flows used in obtaining control of subsidiaries or other businesses	
Other cash receipts from sales of equity or debt instruments of other entities	
Other cash payments to acquire equity or debt instruments of other entities	
Other cash receipts from sales of interests in joint ventures	
Other cash payments to acquire interests in joint ventures	
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	
Proceeds from sales of property, plant and equipment	
Purchase of property, plant and equipment	
Proceeds from sales of investment property	
Purchase of investment property	
Proceeds from sales of intangible assets	
Purchase of intangible assets	
Proceeds from sales of intangible assets under development	
Purchase of intangible assets under development	
Proceeds from sales of goodwill	
Purchase of goodwill	
Proceeds from biological assets other than bearer plants	
Purchase of biological assets other than bearer plants	
Proceeds from government grants	
Proceeds from sales of other long-term assets	
Purchase of other long-term assets	

Cash advances and loans made to other parties	
Cash receipts from repayment of advances and loans made to other parties	
Cash payments for future contracts, forward contracts, option contracts and swap contracts	
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	
Dividends received	
Interest received	
Income taxes paid (refund)	
Other inflows (outflows) of cash	
Net cash flows from (used in) investing activities	-0.9
Cash flows from used in financing activities	
Proceeds from changes in ownership interests in subsidiaries	
Payments from changes in ownership interests in subsidiaries	
Proceeds from issuing shares	
Proceeds from issuing other equity instruments	
Payments to acquire or redeem entity's shares	
Payments of other equity instruments	
Proceeds from exercise of stock options	
Proceeds from issuing debentures notes bonds etc	
Proceeds from borrowings	
Repayments of borrowings	31.
Payments of finance lease liabilities	
Payments of lease liabilities	
Dividends paid	
Interest paid	2.
Income taxes paid (refund)	

Other inflows (outflows) of cash	0
Net cash flows from (used in) financing activities	-34.74
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	-6.11
Effect of exchange rate changes on cash and cash equivalents	
Effect of exchange rate changes on cash and cash equivalents	0
Net increase (decrease) in cash and cash equivalents	-6.11
Cash and cash equivalents cash flow statement at beginning of period	13.27
Cash and cash equivalents cash flow statement at end of period	7.16